Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.

MLA

Yu, Ming-Whei, et al. “Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.” Cancers, vol. 14, no. 23, Dec. 2022, p. 6012. EBSCOhost, https://doi.org/10.3390/cancers14236012.

APA

Yu, M.-W., Lin, C.-L., Liu, C.-J., Wu, W.-J., Hu, J.-T., & Huang, Y.-W. (2022). Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Cancers, 14(23), 6012. https://doi.org/10.3390/cancers14236012

Chicago

Yu, Ming-Whei, Chih-Lin Lin, Chun-Jen Liu, Wan-Jung Wu, Jui-Ting Hu, and Yi-Wen Huang. 2022. “Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B.” Cancers 14 (23): 6012. doi:10.3390/cancers14236012.